Objective To investigate the clinical efficacy of Rabeprazole combined with Flupentixol and Melitracen in the treatment of chronic gastritis.Methods Sixty patients with chronic gastritis admitted to Zaozhuang Traditional Chinese Medicine Hospital from May 1,2019 to June 1,2022 were selected as the research objects,and they were divided into control group (30 cases)and study group (30 cases)according to random number table method.Moxapride was taken orally in both groups,on the basis of which Rabeprazole was added to control group,and Rabeprazole combined with Flupentixol and Melitracen was given to study group.Symptom score,comprehensive treatment effect,depression,anxiety,health status and sleep disorder were compared between the two groups.Results Symptom score of the study group after treatment was lower than that of the control group,and the difference was statistically significant (P＜0.05).The total effective rate of the study group was higher than that of the control group,and the difference was statistically significant(P＜0.05).The score of anxiety and depression in the study group after treatment was lower than that in the control group,and the difference was statistically significant (P＜0.05).The health level of the study group after treatment was higher than that of the control group,and the difference was statistically significant (P＜0.05).The sleep disorder score of the study group was lower than that of the control group after treatment,and the difference was statistically significant (P＜0.05).Conclusion In patients with chronic gastritis,Rabeprazole combined with Flupentixol and Melitracen can significantly improve depression,anxiety and sleep disorders,relieve symptoms of chronic gastritis,and improve comprehensive treatment effect,health level and quality of life.